IQWiG

IQWiG
Name	Institute for Quality and Efficiency in Health Care
Native name	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Formed	2004
Headquarters	Bonn, North Rhine-Westphalia

IQWiG

The Institute for Quality and Efficiency in Health Care is a German statutory agency established to evaluate health technology assessment and provide evidence-based assessments for statutory health insurance decisions. It operates within national social law frameworks and interacts with European agencies, academic centres, and clinical networks to translate systematic reviews into guidance for regulators, payers, and clinicians. The institute's outputs have influenced reimbursement, licensing, and clinical practice across Germany and informed comparative assessments used by European Commission initiatives and international HTA collaborations.

History and establishment

The institute was founded following legislative reforms under the German Social Code that responded to debates involving the Federal Joint Committee, Bundestag, Federal Ministry of Health (Germany), and stakeholder groups including the German Medical Association, German Hospital Federation, National Association of Statutory Health Insurance Funds, and patient organizations. Its establishment drew on precedents such as the National Institute for Health and Care Excellence, the Agency for Healthcare Research and Quality, the Canadian Agency for Drugs and Technologies in Health, and the Swedish Agency for Health Technology Assessment and Assessment of Social Services. Early milestones included integration of methodological guidance from the Cochrane Collaboration and interaction with university centres like Charité – Universitätsmedizin Berlin and Heidelberg University Hospital.

Structure and governance

Governance arrangements link the institute to oversight by the Federal Joint Committee while ensuring statutory independence through board and advisory committees comprising representatives from the Federal Ministry of Health (Germany), payers such as the National Association of Statutory Health Insurance Funds, provider organizations like the German Hospital Federation and the German Medical Association, patient groups, and academic experts from institutions including University of Cologne, University of Hamburg, Ludwig Maximilian University of Munich, and RWTH Aachen University. The organisational design includes methodological departments that interact with research networks such as the German Network for Health Technology Assessment and international partners like the European Network for Health Technology Assessment and the World Health Organization.

Mandate and responsibilities

The institute's legal remit derives from the German Social Code Book V and encompasses benefit assessments for pharmaceuticals post-authorization, comparative evaluations of medical devices, systematic reviews of diagnostics, and health economic analyses for interventions considered by the Federal Joint Committee. Responsibilities include producing rapid assessments, full systematic reviews, early benefit assessments related to the AMNOG pricing framework, and methodological guidance for clinical trial endpoints used by regulatory bodies such as the European Medicines Agency and national competent authorities. The institute's scope intersects with hospital decision-making in centres like Charité – Universitätsmedizin Berlin and reimbursement policy debated in the Bundesverfassungsgericht.

Methodology and assessment processes

Assessment methods combine systematic review techniques pioneered by the Cochrane Collaboration, risk-of-bias frameworks aligned with Cochrane Risk of Bias Tool developments, grading approaches akin to GRADE Working Group recommendations, and modelling practices used in submissions to the European Network for Health Technology Assessment. Processes include scoping with stakeholders such as the German Federation of Patients' Organizations, drafting benefit dossiers in collaboration with manufacturers similar to procedures at the National Institute for Health and Care Excellence, public consultation phases that echo practices at the U.S. Food and Drug Administration, and formal deliberation by expert panels composed of clinicians from centres like University Hospital Heidelberg and statisticians from institutions such as Technische Universität München.

Major reports and impact on German healthcare

Key assessments have concerned high-cost pharmaceuticals, diagnostics, and surgical interventions, influencing pricing under the AMNOG framework, coverage decisions by the Federal Joint Committee, and prescribing practices across hospital systems including University Hospital Hamburg-Eppendorf and Mannheim University Medical Centre. Notable topics have included oncology drugs evaluated in the context of trials registered at European Clinical Trials Database, comparative effectiveness of devices reviewed in light of European conformity assessment processes, and diagnostic accuracy studies referencing standards from International Statistical Classification of Diseases and Related Health Problems. The institute's outputs have shaped debates in the Bundestag and policy documents produced by the Federal Ministry of Health (Germany), and have been cited in academic work at Free University of Berlin, University of Freiburg, and international journals.

Criticism and controversies

Critiques have arisen from pharmaceutical companies represented by the German Pharmaceutical Industry Association, clinicians affiliated with specialist societies such as the German Society of Cardiology, patient advocacy groups, and legal challenges brought before tribunals including the Federal Administrative Court (Germany). Controversies often centre on methodological choices—comparators, surrogate endpoints debated in oncology contexts at centres like University Hospital Essen, and health economic modelling assumptions referenced against European Medicines Agency assessments. Debates involve transparency and stakeholder engagement practices compared with entities such as the National Institute for Health and Care Excellence and the Institute for Clinical and Economic Review, and tensions over the institute's influence on pricing negotiations mediated by the National Association of Statutory Health Insurance Funds.

Category:Health technology assessment organizations